Cytonics

Cytonics

Growth Stage

Developing diagnostics and therapeutics for osteoarthritis

Developing diagnostics and therapeutics for osteoarthritis

Overview

Raised this Round: Raised: $1,695,868

Total Commitments ($USD)

Platform

Dealmaker Securities

Start Date

01/02/2023

Close Date

03/31/2023

Min. Goal
$25,000
Max. Goal
$1,951,220
Min. Investment

$1,000

Security Type

Equity - Preferred

Series

Series C

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.30

Pre-Money Valuation

$58,915,995

Year Founded

2006

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B/B2C

Margin

Low

Capital Intensity

High

Location

Jupiter, Florida

Business Type

Growth

Cytonics, with a valuation of $58.9 million, is raising funds on Dealmaker Securities. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system concentrating A2M from patients’ blood to treat their own damaged joints. The company has a strong IP portfolio with 22 issued US and international patents. Gaetano Scuderi founded Cytonics Corporation in July 2006. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1.9 million. The campaign proceeds will be used for GMP manufacturing of CYT-108, phase 1 human clinical trial, and working capital.

Summary Profit and Loss Statement

FY 2021 FY 2020

Revenue

$307,500

$591,056

COGS

$2,205,358

$503,906

Tax

$0

$0

 

 

Net Income

$-22,544,189

$-995,850

Summary Balance Sheet

FY 2021 FY 2020

Cash

$967,757

$537,354

Accounts Receivable

$341,193

$283,676

Total Assets

$1,756,758

$1,466,746

Short-Term Debt

$554,929

$2,400,661

Long-Term Debt

$0

$107,502

Total Liabilities

$554,929

$2,508,163

Financials as of: 01/02/2023
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Cytonics 05/27/2024 StartEngine $65,792,080 $3,626,034 Equity - Preferred Funded RegCF
Cytonics 03/30/2023 Dealmaker Securities $58,915,995 $1,695,868 Equity - Preferred Funded RegCF
Cytonics 10/13/2022 SeedInvest $58,915,996 $2,633,766 Equity - Preferred Funded RegCF / RegD 506(c)
Cytonics 04/29/2021 SeedInvest $46,701,000 $4,667,638 Equity - Preferred Funded RegA+
Cytonics 05/17/2019 SeedInvest $32,400,000 $494,344 Convertible Note Funded RegCF / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Cytonics on Dealmaker Securities 2023
Platform: Dealmaker Securities
Security Type: Equity - Preferred
Valuation: $58,915,995
Price per Share: $2.30

Follow company

Follow Cytonics on Dealmaker Securities 2023

Buy Cytonics's Deal Report

Warning: according to the close date for this deal, Cytonics may no longer be accepting investments.

Cytonics Deal Report

Get KingsCrowd’s comprehensive report on Cytonics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Cytonics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Cytonics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge